Edesa Biotech Inc
NASDAQ:EDSA
Edesa Biotech Inc
Operating Income
Edesa Biotech Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Edesa Biotech Inc
NASDAQ:EDSA
|
Operating Income
-$8.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Zymeworks Inc
NYSE:ZYME
|
Operating Income
-$138.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Operating Income
-$116.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Operating Income
-$99.2m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Operating Income
-$91.7m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-36%
|
|
Spectral Medical Inc
TSX:EDT
|
Operating Income
-CA$11.7m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
0%
|
See Also
What is Edesa Biotech Inc's Operating Income?
Operating Income
-8.7m
USD
Based on the financial report for Dec 31, 2023, Edesa Biotech Inc's Operating Income amounts to -8.7m USD.
What is Edesa Biotech Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-7%
Over the last year, the Operating Income growth was 44%. The average annual Operating Income growth rates for Edesa Biotech Inc have been -3% over the past three years , -11% over the past five years , and -7% over the past ten years .